86 results about "Lung infection" patented technology

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The invention is suitable for the technical field of model prediction, and provides a method and system for constructing a pulmonary infection risk prediction model based on machine learning, and the method comprises the following steps: collecting data information, and carrying out the standardization processing of the data information, the data information comprising structured data, image data, time series data and environment data; performing multi-modal feature extraction based on the data information to obtain an image feature F1, a physiological time sequence feature F2 and an environment feature F3; performing multi-modal feature fusion, determining weights of the image features, the physiological time sequence features and the environment features, and adaptively adjusting the weights of the environment features based on seasonal factors; processing class imbalance through focus loss, determining a time decay weight according to infection latency characteristics, and determining a total loss function; and carrying out model training by adopting a multi-layer perceptron to obtain a pulmonary infection risk prediction model. According to the invention, by introducing the seasonal factor and the seasonal sensitivity coefficient, adaptive adjustment of the environmental feature weight is realized.

The invention discloses a thoracic surgery pulmonary infection effusion drainage device and belongs to the technical field of medical instruments, the thoracic surgery pulmonary infection effusion drainage device comprises a drainage catheter structure, a filtering structure and a connecting assembly, the drainage catheter structure comprises an insertion tube, the two ends of the insertion tube are connected with a fixing tube and a hemispherical end respectively, and a partition plate is arranged in the insertion tube and the fixing tube; a plurality of drainage holes are formed in the end, close to the hemispherical end, of the insertion tube in the circumferential direction, and a medicine feeding hole is formed in the portion, above the drainage holes, of the insertion tube and communicated with the monitoring cavity. By means of the semispherical end and the drainage hole of the drainage catheter structure, lung tissue is prevented from being scratched when thoracic wall puncture is conducted, the lung tissue damage rate can be reduced to be smaller than or equal to 0.5%, drainage, pressure monitoring and drug administration are achieved through the double-cavity structure, one-time puncture is completed, and the pain of a patient is relieved; by arranging the partition plate, the drainage cavity and the monitoring cavity are isolated, liquid medicine is prevented from polluting an effusion sample, and the infection risk is reduced.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention discloses a bacteriophage gel microsphere as well as a preparation method and application thereof. The preparation method is simple and easy to implement and convenient to operate and popularize. Meanwhile, the prepared bacteriophage gel microspheres are high in loading capacity and can effectively load bacteriophages, the high porosity and the porous structure can provide a large number of binding sites for the bacteriophages, the contact opportunity of the bacteriophages and bacteria is increased, and the antibacterial efficiency is improved. In addition, the hydrogel property of the bacteriophage gel microspheres can protect the bacteriophage from being influenced by adverse environmental factors such as dryness and high temperature, and the stability of the bacteriophage in practical application is improved. In addition, compared with bacteriophage hydrogel microspheres prepared in the prior art, the bacteriophage gel microspheres prepared in the invention have smaller particle size, so that multi-way administration modes such as treatment of pulmonary infection by atomization administration and the like can be carried out.

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention belongs to the technical field of nano diagnosis and treatment agents, and particularly relates to a preparation method and application of a multi-field response type nano diagnosis and treatment agent, the preparation method of the multi-field response type nano diagnosis and treatment agent comprises a core layer, a middle shell layer and an outer wrapping layer, the core layer is DCNPs, the middle shell layer is Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs, and the outer wrapping layer is an Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs. And the outer coating layer is HA which is coated on the outer side of the Nd < 0.03 > Fe < 0.97 > Se < 2 >. According to the invention, a multi-mode therapy of membrane structure defect induction-oxidative stress-metabolism interference-energy blocking can be realized, the mucous barrier penetrating ability is good, the retention ability of DNH in a pulmonary infection focus is improved, efficient drug delivery is realized, real-time NIR-II diagnosis can be assisted, and the application prospect is wide. The efficient treatment of lung bacterial infection diseases is realized.

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Compositions, kits, and systems are disclosed that contain at least one senolytic agent. The compositions, kits, and systems may be utilized, for example, in a method of treating at least one lung infection in a patient. In a particular (but non-limiting) embodiment, the compositions, kits, and systems may be utilized in a method of treating at least one infection in a cystic fibrosis patient.

The invention discloses a compound traditional Chinese medicine composition for adjuvant therapy of cerebral hemorrhage combined with pulmonary infection. The compound traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-60 parts of ephedra, 90-120 parts of gypsum, 30-50 parts of almond, 150-180 parts of raw astragalus membranaceus, 100-120 parts of radix stephaniae tetrandrae, 90-120 parts of ginseng, 60-80 parts of radix bupleuri, 40-60 parts of fructus aurantii, 20-40 parts of platycodon grandiflorum, 150-180 parts of honey-fried licorice root, 45-80 parts of mint and 3-4 parts of borneol. The compound traditional Chinese medicine composition disclosed by the invention can be prepared into a dosage form of spray, and compared with traditional decoction for oral administration, the compound traditional Chinese medicine composition is convenient to use and less in liquid intake, and meanwhile, gastrointestinal reaction and vomiting are avoided, and the risk of secondary aspiration is reduced.

Blood and lung infection is a worldwide health problem, and about five millions of cases of death each year. Early treatments can help rescue life but require better tests to identify these infections. The invention recognizes pathogens, in particular those having antibiotic resistance, more quickly. The invention allows appropriate antibiotic treatment to be performed at an earlier point in time. Data from deep RNA sequencing of human blood is used to create a faster diagnostic test against infection and related antimicrobial resistance.

The present disclosure relates to a lung infection area segmentation method and device, an electronic device and a storage medium. The method comprises: performing feature extraction processing on a lung image to obtain a plurality of high-level features; performing multi-scale fusion processing on the high-level features to obtain high-level enhanced features; performing global information extraction on the high-level enhanced features to obtain global guidance features; and performing multi-layer feature interaction processing on the high-level features by using the global guidance features to obtain lung features, wherein the lung features are used to represent a lung infection area of the lung image. The embodiments of the present disclosure can improve the lung infection area segmentation accuracy.

Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed. Kits including tafenoquine and means for testing for a viral infection are disclosed.

The invention discloses a polyclonal antibody for treating pulmonary infection as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: culturing pathogenic bacteria causing pulmonary infection by taking pig lung tissues as a culture medium, collecting the tissues, and homogenizing to obtain homogenate; performing antigen extraction and purification treatment on the homogenate, and performing inactivation treatment to obtain an inactivated antigen; immunizing a horse with the inactivated antigen, and collecting and separating to obtain serum; and carrying out antibody extraction and purification on the serum to obtain the polyclonal antibody. The prepared polyclonal antibody has the advantages of strong neutralization broad spectrum, high neutralization activity and good pulmonary infection treatment effect.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

The present specification provides methods and compositions for treating fibrosis, in particular pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or occur after a pulmonary infection. The pulmonary infection may be caused by SARS-CoV-2. Lung function is stabilized or improved due to treatment.

The present invention relates to the field of medical instruments, and in particular to a subglottic drainage and flushing device suitable for outdoor environments, comprising an endotracheal tube, a balloon pressure measuring assembly being installed on the surface of the endotracheal tube, a balloon being provided on the surface of the endotracheal tube, a drainage tube being fixedly connected to the surface of the endotracheal tube, one end of the drainage tube being movably connected to a medical three-way tube, one end of the medical three-way tube being movably connected to a third connecting tube, a negative pressure suction assembly being movably installed on the other end of the medical three-way tube, a heating assembly being detachably connected to the surface of the third connecting tube, and one end of the third connecting tube being movably connected to a physiological saline bag. The flushing device can be controlled by a motor so that the pressure of the physiological saline is controllable during flushing, thereby preventing excessive pressure from forming a gap between the balloon and the airway wall or even causing damage to the balloon, leading to lung infection in the patient, and thereby facilitating the subglottic flushing operation of medical personnel.

The invention discloses a lung infection image segmentation method based on bidirectional guide multi-scale feature decoding, and the method comprises the steps: firstly receiving lung CT image data, carrying out the preprocessing, generating standardized image data, carrying out the hierarchical feature coding of the standardized image data based on a Swin Transform architecture, and generating multi-scale feature representation. And finally, on the basis of multi-scale feature representation, adopting a progressive two-way guide multi-scale feature decoding strategy to realize adaptive enhancement, two-way guide fusion and multi-scale decoding of coding features, and generating a pulmonary infection focus segmentation result map. According to the invention, lesions with different sizes and shapes can be better processed, and accurate segmentation of different types of lesions can be realized.

The invention provides a functionalized biological vesicle, which is characterized in that an extracellular vesicle membrane of inactivated bacteria is used as a carrier, and L-arginine, NADPH (Nicotinamide Adenine Dinucleotide Phosphate) and NO fluorescent probes are wrapped in the vesicle membrane to form a nano-scale vesicle. The invention also provides a preparation method and application of the functionalized biological vesicle. In addition, the invention also provides a pulmonary infection detection kit and a non-diagnostic / therapeutic pulmonary infection detection method. According to the invention, L-arginine, NADPH and the like are wrapped by an extracellular vesicle membrane of inactivated bacteria to form a functionalized biological vesicle, and the problem that the existing FeNO detection is insufficient in accuracy and specificity in lung infection diagnosis is solved through the vesicle, so that non-invasive, rapid and accurate lung infection diagnosis is realized; meanwhile, the problems that in an existing lung infection diagnosis method, sputum culture is prone to pollution, the positive rate is low, imaging examination early sensitivity is insufficient, radiation exists, and the cost is high are solved.

The present invention relates to the field of antibody technology, and specifically to a method for preparing and applying a recombinant monoclonal antibody against rT3. The present invention utilizes phage display technology to screen and obtain the rT3 recombinant rabbit monoclonal antibody of the present invention, wherein the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:1; and the light chain variable region thereof has the amino acid sequence shown in SEQ ID NO:2. The monoclonal antibody has strong specificity and high detection sensitivity, and solves the problem of low rT3 content in samples and high detection difficulty. It has been identified that repeated multiple detections using the monoclonal antibody have good stability and high accuracy. The antibody is used for the detection of rT3 content in serum, and combined with other thyroid index tests and clinical manifestations, it can diagnose hyperthyroidism and hypothyroidism, and is also clinically significant in the detection of diabetes, lung infection, myocardial infarction, cirrhosis, uremia, and some cancers.

The present invention relates to a combination therapy for treating infections caused by bacteria of the genus Mycobacterium and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulator compounds.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.

The invention discloses a composition, a kit and a detection method for detecting pulmonary infection pathogens. The composition comprises at least one of a component A, a component B, a component C and a component D, the component A comprises a primer pair SEQ ID NO: 1-2 and a probe SEQ ID NO: 3; detecting bordetella pertussis by the component A; the component B comprises a primer pair SEQ ID NO: 4-5 and a probe SEQ ID NO: 6; the component B is used for detecting Nocardia; the component C comprises a primer pair SEQ ID NO: 7-8 and a probe SEQ ID NO: 9; detecting cryptococcus neoformans by the component C; the component D comprises a primer pair SEQ ID NO: 10 to 11 and a probe SEQ ID NO: 12; the component D is used for detecting acinetobacter baumannii. The composition for detecting the pulmonary infection pathogens provided by the invention can detect and distinguish at least one of bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, has higher sensitivity, specificity and precision, can accurately and quickly detect bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, and can be used for detecting the pulmonary infection pathogens. The detection efficiency is improved, the detection period is shortened, and detection is convenient.

The present invention discloses a forsythiaside phospholipid complex and its preparation method and application, which belong to the field of medical technology. The forsythiaside phospholipid complex includes forsythiaside and phospholipid, and its preparation method includes dissolving a certain proportion of forsythiaside and phospholipid in an organic solvent and stirring the reaction in a constant temperature water bath, and then subjecting the reaction solution to reduced pressure rotary evaporation and vacuum drying to obtain the forsythiaside phospholipid complex. The forsythiaside phospholipid complex prepared by the present invention can be prepared as an oral preparation on the one hand to improve oral bioavailability and drug distribution in lung tissue, and on the other hand, it can be prepared into a suspension by hydration, and the drug can be delivered to the lungs by intravesical instillation to treat interstitial cystitis, or delivered to the lungs by atomized inhalation to prolong the lung residence time and lung drug exposure. Compared with conventional original drug preparations, the forsythiaside phospholipid complex of the present invention significantly improves the efficacy of treating interstitial cystitis and the anti-inflammatory effect of inflammation caused by lung infection viruses and bacteria.

The present invention relates to the field of biomedicine, and specifically relates to the use of a recombinant protein in the preparation of a Pseudomonas aeruginosa vaccine, characterized in that the recombinant protein comprises the outer membrane carboxylate channel K6 protein of Pseudomonas aeruginosa, the Pseudomonas aeruginosa vaccine comprises the recombinant protein and an outer membrane porin combination, and the recombinant protein is used to enhance the immune efficacy of the outer membrane porin combination; the outer membrane porin combination comprises outer membrane porin F and outer membrane porin I; wherein, the mass ratio of the recombinant protein to the outer membrane porin combination is 1–3:3. The Pseudomonas aeruginosa vaccine provided by the present invention exhibits better immune protection efficacy (the bacterial clearance rate can reach more than 99%) while having good safety, and has extremely high application value in the prevention and / or treatment of Pseudomonas aeruginosa infection (especially lung infection caused by Pseudomonas aeruginosa).

The invention relates to the technical field of medical artificial intelligence and medical image analysis crossing, and discloses a pulmonary infection auxiliary differential diagnosis system based on a self-supervised pre-training model. Comprising a multi-dimensional data acquisition module, an image preprocessing module, a multi-dimensional data analysis module, a self-supervision pre-training model, a model application module, a model evaluation module and a model optimization module, the multi-dimensional data analysis module carries out feature extraction, multi-modal data fusion and rare case identification on data, the self-supervision pre-training model obtains unlabeled data according to the multi-dimensional data acquisition module, and the model application module applies the self-supervision pre-training model to an actual scene to carry out real-time diagnosis, focus visualization and early warning generation. The model evaluation module carries out analysis and evaluation according to a scene output result, and the model optimization module carries out optimization measures according to evaluation feedback and an active learning strategy.

The present invention discloses the use of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of medical technology. Ferrous ions were used in antibacterial activity tests on Staphylococcus aureus, demonstrating a strong bactericidal effect. When sterilizing Staphylococcus aureus, the survival rate was less than 0.001%, and when sterilizing methicillin-resistant Staphylococcus aureus (MRSA), the survival rate was less than 0.01%. The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA lung infection and effectively and timely prevented the reproduction and spread of microorganisms in the body. This indicates that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.